PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 25660085-0 2015 Anticonvulsant activity of the cyclooxygenase-2 (COX-2) inhibitor etoricoxib in pentylenetetrazole-kindled rats is associated with memory impairment. Etoricoxib 66-76 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 31-47 25660085-0 2015 Anticonvulsant activity of the cyclooxygenase-2 (COX-2) inhibitor etoricoxib in pentylenetetrazole-kindled rats is associated with memory impairment. Etoricoxib 66-76 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 49-54 25660085-2 2015 In the present study, the effect of the selective COX-2 inhibitor etoricoxib on seizures, oxidative stress, and learning and memory was studied. Etoricoxib 66-76 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 50-55 22814015-13 2012 However, etoricoxib which is a COX-2 specific inhibitor, was found to be more effective than the traditional NSAID, indomethacin. Etoricoxib 9-19 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 31-36 23489008-4 2013 These results demonstrate that COX-2 dependent mechanisms play a significant role in blood pressure regulation, and etoricoxib-induced COX-2 inhibition blunts the therapeutic effect of different classes of antihypertensives in this mineralocorticoid volume expansion model of hypertension. Etoricoxib 116-126 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 135-140 22681911-0 2012 Angiostatic role of the selective cyclooxygenase-2 inhibitor etoricoxib (MK0663) in experimental lung cancer. Etoricoxib 61-71 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 34-50 22681911-0 2012 Angiostatic role of the selective cyclooxygenase-2 inhibitor etoricoxib (MK0663) in experimental lung cancer. Etoricoxib 73-79 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 34-50 21701788-10 2012 Besides, improving cognitive dysfunction, chronic administration of highly selective cyclooxygenase-1 and/or cyclooxygenase-2 inhibitors (valeryl salicylate and etoricoxib, respectively), but not cyclooxygenase-3 inhibitor (phenacetin), significantly reduced elevated malondialdehyde, nitrite levels, and restored reduced glutathione and superoxide dismutase levels. Etoricoxib 161-171 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 109-125 20349107-10 2010 CONCLUSIONS: Etoricoxib is effective in neurogenic laryngitis for limited periods of administration, indicating that selective COX-2 inhibitors should be evaluated in the future. Etoricoxib 13-23 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 127-132 20349107-0 2010 The selective COX-2 inhibitor Etoricoxib reduces acute inflammatory markers in a model of neurogenic laryngitis but loses its efficacy with prolonged treatment. Etoricoxib 30-40 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 14-19 20349107-3 2010 The NGI animals were divided into three groups: (1) treated with COX-2 inhibitor Etoricoxib, (2) vehicle and (3) non-intubated animals. Etoricoxib 81-91 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 65-70 21635885-2 2011 Cyclooxygenase-2 mRNA has been shown to be up-regulated after stroke and also the time window of its expression extends from 4 to 12 h. The objective of this study was to elucidate the protective effect of Etoricoxib (a selective Cyclooxygenase-2 inhibitor) against transient middle cerebral artery occlusion induced behavioral, biochemical and histological alterations. Etoricoxib 206-216 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 0-16 21635885-2 2011 Cyclooxygenase-2 mRNA has been shown to be up-regulated after stroke and also the time window of its expression extends from 4 to 12 h. The objective of this study was to elucidate the protective effect of Etoricoxib (a selective Cyclooxygenase-2 inhibitor) against transient middle cerebral artery occlusion induced behavioral, biochemical and histological alterations. Etoricoxib 206-216 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 230-246 20204254-0 2010 Effect of etoricoxib, a cyclooxygenase-2 selective inhibitor on aberrant crypt formation and apoptosis in 1,2 dimethyl hydrazine induced colon carcinogenesis in rat model. Etoricoxib 10-20 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 24-40 20204254-1 2010 Etoricoxib, a second generation selective cyclooxygenase-2 (COX-2) inhibitor had been studied for the chemopreventive response at its therapeutic anti-inflammatory dose in 1,2-dimethylhydrazine (DMH) induced colon carcinogenesis in rat model. Etoricoxib 0-10 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 42-58 20204254-1 2010 Etoricoxib, a second generation selective cyclooxygenase-2 (COX-2) inhibitor had been studied for the chemopreventive response at its therapeutic anti-inflammatory dose in 1,2-dimethylhydrazine (DMH) induced colon carcinogenesis in rat model. Etoricoxib 0-10 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 60-65 17638016-8 2008 Treatment 1 h before IFS injection with etoricoxib, indomethacin, thalidomide, and pentoxifylline reduced COX-2 expression and some macroscopic and microscopic parameters in IFS-induced HC. Etoricoxib 40-50 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 106-111 19392653-0 2009 The cyclooxygenase-2 inhibitor etoricoxib is a potent chemopreventive agent of colon carcinogenesis in the rat model. Etoricoxib 31-41 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 4-20 20192600-1 2009 Etoricoxib, a highly selective cyclooxygenase- 2 (COX-2) inhibitor (a non steroidal anti-inflammatory drug) used for the treatment of rheumatoid arthritis and osteoarthritis, has been newly marketed and studied for the chemopreventive response in the 1,2-dimethylhydrazine dihydrochloride (DMH) induced rat colon cancer model. Etoricoxib 0-10 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 31-48 20192600-1 2009 Etoricoxib, a highly selective cyclooxygenase- 2 (COX-2) inhibitor (a non steroidal anti-inflammatory drug) used for the treatment of rheumatoid arthritis and osteoarthritis, has been newly marketed and studied for the chemopreventive response in the 1,2-dimethylhydrazine dihydrochloride (DMH) induced rat colon cancer model. Etoricoxib 0-10 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 50-55 20192600-13 2009 Studies of a nuclear transcription factor (NF-kB) and COX-2 by Western blot analysis and immunohistochemistry demonstrated expression of both to be elevated in the DMH treated group but reduced in the DMH + Etoricoxib group. Etoricoxib 207-217 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 54-59 19105535-0 2008 Cyclooxygenase-2 inhibition by etoricoxib modulates plasma membrane fluidity in rat colon. Etoricoxib 31-41 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 0-16 17452571-6 2007 Etoricoxib improved the sleep parameters, suggesting the involvement of the cyclo-oxygenase-2 enzyme in acute inflammation of the TMJ, specifically in REM sleep. Etoricoxib 0-10 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 76-93 34238176-11 2022 In addition, Etoricoxib significantly down-regulated the protein expression of interleukin 1 beta (IL-1beta), tumor necrosis factor alpha (TNFalpha), nuclear Factor-kappa B (NF-kappaB), phosphorylated nuclear Factor-kappa B (p-NF-kappaB), cyclooxygenase-2 (COX-2), and prostaglandin E2 (PGE2). Etoricoxib 13-23 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 239-255 16182319-2 2006 The present study was aimed to assess any possible interaction (additive or potentiation) in the antinociceptive effects of etoricoxib; a novel cyclooxygenase-2 inhibitor, and tramadol; a typical opioid agonist when administered in combination against mechanical hyperalgesia induced by spinal cord injury in rats. Etoricoxib 124-134 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 144-160 15853965-0 2005 Protective effects of etoricoxib, a selective inhibitor of cyclooxygenase-2, in experimental periodontitis in rats. Etoricoxib 22-32 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 59-75 15853965-1 2005 BACKGROUND: The purpose of the present study was to evaluate the effect of a potent selective cyclooxygenase-2 (COX-2) inhibitor, etoricoxib, on the prevention of alveolar bone loss in experimental periodontitis induced in rats. Etoricoxib 130-140 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 94-110 15853965-1 2005 BACKGROUND: The purpose of the present study was to evaluate the effect of a potent selective cyclooxygenase-2 (COX-2) inhibitor, etoricoxib, on the prevention of alveolar bone loss in experimental periodontitis induced in rats. Etoricoxib 130-140 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 112-117 34238176-11 2022 In addition, Etoricoxib significantly down-regulated the protein expression of interleukin 1 beta (IL-1beta), tumor necrosis factor alpha (TNFalpha), nuclear Factor-kappa B (NF-kappaB), phosphorylated nuclear Factor-kappa B (p-NF-kappaB), cyclooxygenase-2 (COX-2), and prostaglandin E2 (PGE2). Etoricoxib 13-23 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 257-262 34238176-12 2022 CONCLUSION: In conclusion, the current results proved that etoricoxib possesses an anticarcinogenic effect via its antioxidant, anti-inflammatory, and modulation of NF-kappaB/COX-2/PGE2 signaling. Etoricoxib 59-69 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 175-180 32818660-1 2020 OBJECTIVES: The non-steroidal anti-inflammatory drug etoricoxib is the most highly selective inhibitor of cyclooxygenase-2 available (344:1) and has been approved for postoperative pain therapy following dental interventions in Europe. Etoricoxib 53-63 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 106-122